Vancouver BC – May 14, 2018 – WAT Medical’s leading product to treat nausea-induced vomiting, EmeTerm, has received its FDA clearance earlier in April. Now ready to officially enter the U.S. market as an effective medical treatment. WAT Medical is thrilled to bringing its innovative technology to help the millions of people who suffer from such conditions. The product is effective for a wide range of treatments, including all types of motion sickness induced by travelling and morning sickness from pregnancy. EmeTerm allows its users to be free from medication side effects like dizziness, drowsiness and thickened lung secretions.
EmeTerm’s technology is called neuromodulation, which is FDA cleared and clinical proven. The electric current is sent by the peripheral nervous system via P6 acupuncture point on the underside of the wrist. The electric pulses are delivered to their targets in the brain and precisely block the emesis signals from brain to stomach. EmeTerm are currently used by consumers in over 20 counties worldwide.
EmeTerm is the winner of 2017 iF Design Award for its innovative design and usability. The patented electrodes design enhances the transfer of electric pulses from device to skin. No conduct gel is needed, which increases convenience and affordability to consumers.
WAT Medical’s anti-migraine device, HeadaTerm, is also in the process of FDA clearance, and is estimated to enter the U.S. market along with EmeTerm in the following months.
WAT Medical will be attending FIME 2018, Florida International Medical Expo, the largest medical trade fair across America, on July 17-19 (Booth No.: BQ 85). Both EmeTerm and HeadaTerm will be featured.
For more information, please visit WAT Medical Enterprise Ltd.’s website at www.watmedical.com